Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)ERK Inhibitor JSI-1187 in Advanced Solid Tumors
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- JS InnoPharm, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06239623
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- JS InnoPharm, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT04418167
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
News
No news found